ES2156587T3 - Bispecific molecules that recognize antigen starter lymphocytic CD2 and tumor antigens. - Google Patents

Bispecific molecules that recognize antigen starter lymphocytic CD2 and tumor antigens.

Info

Publication number
ES2156587T3
ES2156587T3 ES94111346T ES94111346T ES2156587T3 ES 2156587 T3 ES2156587 T3 ES 2156587T3 ES 94111346 T ES94111346 T ES 94111346T ES 94111346 T ES94111346 T ES 94111346T ES 2156587 T3 ES2156587 T3 ES 2156587T3
Authority
ES
Spain
Prior art keywords
cd2
lymphocytic
starter
recognize antigen
tumor antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94111346T
Other languages
Spanish (es)
Inventor
Wolfgang Dr Strittmatter
Carlota-Silvia Jaggle
Stefan Prof Dr Meuer
Burkhart Dr Shraven
Martin Wild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP93112330 priority Critical
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2156587T3 publication Critical patent/ES2156587T3/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation

Abstract

LA PRESENTE INVENCION ES RELATIVA A NUEVOS Y ALTAMENTE EFECTIVOS FRAGMENTOS DE ANTICUERPO BIESPECIFICOS QUE RECONOCEN ANTIGENO CD2 DE LINFOCITO Y ALGUNOS ANTIGENOS VARIABLES DE TUMOR. The present invention is ON NEW AND HIGHLY EFFECTIVE bispecific antibody fragments LYMPHOCYTE RECOGNIZE ANTIGEN CD2 VARIABLES AND TUMOR some antigens. ADEMAS, LA INVENCION ES RELATIVA A DOS NUEVOS ANTICUERPOS MONOCLONALES DENOMINADOS ALCD2.M1 Y ALCD2.M2. Furthermore, the invention IS ON TWO NEW MONOCLONAL antibodies called ALCD2.M1 And ALCD2.M2. UNA COMBINACION DE ESTOS ANTICUERPOS, DONDE AL MENOS UNO DE ELLOS ES UN FRAGMENTO DE ANTICUERPO BIESPECIFICO, PUEDE SER USADO AFORTUNADAMENTE EN TERAPIA Y DIAGNOSTICOS TUMORALES. A combination of these antibodies, wherein at least one of them is a bispecific antibody fragment, CAN BE USED IN THERAPY AND DIAGNOSTICS FORTUNATELY TUMOR.
ES94111346T 1993-08-02 1994-07-21 Bispecific molecules that recognize antigen starter lymphocytic CD2 and tumor antigens. Expired - Lifetime ES2156587T3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP93112330 1993-08-02

Publications (1)

Publication Number Publication Date
ES2156587T3 true ES2156587T3 (en) 2001-07-01

Family

ID=8213129

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94111346T Expired - Lifetime ES2156587T3 (en) 1993-08-02 1994-07-21 Bispecific molecules that recognize antigen starter lymphocytic CD2 and tumor antigens.

Country Status (19)

Country Link
US (1) US5798229A (en)
EP (1) EP0637593B1 (en)
JP (2) JP3822653B2 (en)
KR (1) KR100347465B1 (en)
AT (1) AT199378T (en)
AU (1) AU683659B2 (en)
CA (1) CA2129183C (en)
CZ (1) CZ291071B6 (en)
DE (2) DE69426743D1 (en)
DK (1) DK0637593T3 (en)
ES (1) ES2156587T3 (en)
GR (1) GR3035926T3 (en)
HU (1) HU218100B (en)
NO (1) NO942850L (en)
PL (1) PL176761B1 (en)
PT (1) PT637593E (en)
RU (1) RU2203319C2 (en)
SK (1) SK283133B6 (en)
ZA (1) ZA9405753B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0826696T3 (en) * 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Use of bi- and trispecific antibodies for inducing a tumor immunity
AT210682T (en) * 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Destruction of contaminating tumor cells in stem cell transplants with bispecific antibodies
JP4786793B2 (en) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス,インコーポレイティド Therapeutic and diagnostic applications based on the role of CXCR-4 gene in tumorigenesis
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
ID28117A (en) * 1998-07-10 2001-05-03 Connex Gmbh Immunological reagents that specifically interact with the extracellular domain of the human zeta chain
WO2000018806A1 (en) * 1998-09-25 2000-04-06 Horst Lindhofer Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
PT1210428E (en) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, a receptor for b7-4, and uses therefor
MXPA03008959A (en) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, a receptor for b7-4, and uses therefor.
AT502293B1 (en) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogenic monoclonal antibody
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc Methods of preventing or treating cell malignancies by administering cd2 antagonists
EP3301114A1 (en) 2002-10-16 2018-04-04 Purdue Pharma LP Fusion polypeptides of antibodies that bind cell-associated ca 125/o722p
US20050031625A1 (en) * 2003-03-28 2005-02-10 Elusys Therapeutics, Inc. Methods and compositions for conversion of antibody activity
WO2005005479A1 (en) * 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
JP2007510738A (en) * 2003-11-06 2007-04-26 アイコス、コーポレーションIcos Corporation CD11d (α-d) methods for treating chronic pain using a composition that specifically binds to integrin
WO2005057223A2 (en) * 2003-12-04 2005-06-23 Applied Research Systems Ars Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
CA2585849A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
TWI544076B (en) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibodies modified method for the purification of bispecific antibody
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Methods for modifying the isoelectric point of the antibody by amino acid substitutions Cdr
PE07112009A1 (en) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd constant region antibody mutant
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
MX2011003195A (en) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
CA2749501C (en) 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Antibody constant region variant
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN104945509A (en) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
WO2011060272A2 (en) 2009-11-13 2011-05-19 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CN105085681B (en) * 2009-12-02 2018-12-28 伊麦吉纳博公司 Target the J591 miniantibody and double antibody of human prostate-specific membrane antigen
SI2949670T1 (en) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
MX2012007497A (en) * 2009-12-25 2012-08-01 Chugai Pharmaceutical Co Ltd Polypeptide modification method for purifying polypeptide multimers.
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag bispecific antibodies
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibody containing disulfide-stabilized Fv fragment
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
CA2831572A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP3418306A1 (en) * 2011-10-11 2018-12-26 F. Hoffmann-La Roche AG Improved assembly of bispecific antibodies
US10023643B2 (en) * 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
ES2597228T3 (en) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedure for the selection and production of objectification entities, as targets, highly selective and multispecific, custom, which contain at least two different binding entities, and use thereof
EP3004877A4 (en) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
RU2663104C1 (en) * 2017-07-13 2018-08-01 Общество с ограниченной ответственностью "Реал Таргет" Producing pegylated fragments of gd2-specific antibodies inducing direct cell death of gd2-positive tumor cells, and use thereof in therapy of gd2-positive tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE260880T1 (en) * 1986-09-11 1988-11-03 Dana-Farber Cancer Institute, Inc., Boston, Mass., Us Method for triggering cytotoxicity.
ES2073394T3 (en) * 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc Bifunctional antibody constructs and their use for selectively destroying cell populations.
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
HU219537B (en) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanized and chimeric monoclonal antibodies, pharmaceutical compositions comprising them, expression vectors containing coding sequences of the antibodies, and methods of preparing antibodies

Also Published As

Publication number Publication date
DE69426743D1 (en) 2001-04-05
CZ291071B6 (en) 2002-12-11
DE69426743T2 (en) 2001-08-16
JP4231862B2 (en) 2009-03-04
AU6869894A (en) 1995-02-09
JP3822653B2 (en) 2006-09-20
NO942850D0 (en) 1994-08-01
JPH0789873A (en) 1995-04-04
PL176761B1 (en) 1999-07-30
AT199378T (en) 2001-03-15
PT637593E (en) 2001-08-30
CA2129183A1 (en) 1995-02-03
JP2005336207A (en) 2005-12-08
ZA9405753B (en) 1995-03-15
SK91294A3 (en) 1996-11-06
CZ180294A3 (en) 1995-02-15
NO942850L (en) 1995-02-03
AU683659B2 (en) 1997-11-20
GR3035926T3 (en) 2001-08-31
DK637593T3 (en)
US5798229A (en) 1998-08-25
HUT71309A (en) 1995-11-28
HU9402220D0 (en) 1994-10-28
CA2129183C (en) 2006-05-16
RU2203319C2 (en) 2003-04-27
DK0637593T3 (en) 2001-06-25
SK283133B6 (en) 2003-03-04
EP0637593A1 (en) 1995-02-08
HU218100B (en) 2000-06-28
PL304510A1 (en) 1995-02-06
KR950005327A (en) 1995-03-20
KR100347465B1 (en) 2003-03-03
EP0637593B1 (en) 2001-02-28
RU94028282A (en) 1996-07-20

Similar Documents

Publication Publication Date Title
Augener et al. The reaction of monomeric and aggregated immunoglobulins with Cl
DE69620324T2 (en) Distinctive verification of statements for the recognition of connected digits
SA1151B1 (en) Vaccines
FR2709656B1 (en) Installation for microsurgical operation desktop and processes involved Óoeuvre by said installation.
MXPA02007449A (en) Humanized anti ccr2 antibodies and methods of use therefor.
BR7801478A (en) Process and head for qualitative and quantitative detection of the presence in the atmosphere of combustion gases, complete or imcompletas
TR200200937T2 (en) compositions for the treatment of ovarian cancer.
NO176194B (en) Apparatus for improving the efficiency of fuel combustion
KR880008961A (en) Self-supporting ceramic composite and a method of manufacturing the same
ES2440825T1 (en) Humanized immunoglobulins and their production and use
ES2114051T3 (en) Chelators based on polyamine modified carboxamide and radioactive complexes and conjugates.
DE69401020T2 (en) Emission control apparatus and method for an internal combustion engine
DE3856108T2 (en) Monoclonal antibodies of the second generation having binding specificity for TAG-72 and human carcinomas, and methods for their application
DE186833T1 (en) Cytotoxic protein method thereof to isolate monoclonal antibody CT-1 and the same producing hybridoma.
BR9505980B1 (en) bivalent monoclonal antibody fragment, as well as pharmaceutical composiÇço comprising the same.
DE69536072D1 (en) CDR-exchanged type III anti-CEA humanized mouse monoclonal antibodies
DE69527975D1 (en) Humanized antibody directed against CD38
AR075790A2 (en) Neutralizing anti human -ngf as selective inhibitors via NGF (nerve growth factor)
DE69119278D1 (en) A monoclonal antibody which reacts with a new HLA determinant on MHC class I molecules, and methods for the activation of lymphocytes
GR3035926T3 (en) Bispecific trigger molecules recognizing lymphocyte antigen CD2 and tumor antigens.
ES2079638T3 (en) Humanized antibodies.
DE68911935D1 (en) Variants of the Fiat-Shamir method for identifying and signing.
AT201234T (en) For human tumor necrosis factor-specific monoclonal and chimeric antibodies
DE69109275T2 (en) A process for the isolation of macromolecules by means of magnetically attractable beads which bind macromolecules nonspecific.
ES2123056T3 (en) Bnp antibody and immunoassay that employs him.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637593

Country of ref document: ES